Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Kevin Kalinsky
Columbia University Health Sciences, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Novartis
Other : Spouse works for Novartis - receives salary and stock options
Dr. Kalinsky’s spouse is employed by Novartis, whose Sandoz generics division is one of several commercial entities that distribute generic atorvastatin, a drug that is part of this study. In light of these facts, Columbia found that Dr. Kalinsky’s significant financial interest in Novartis (through his spouse) could affect the design, conduct, or reporting of the R03 research.
Pre-Surgical trial of Metformin and Atorvastatin in Operable Breast Cancer
In pre-surgical studies, women who have been newly diagnosed with an operable breast cancer will start on a study drug or combination of drugs between the time of their diagnosis and definitive removal of their breast cancer (i.e. approximately 2-4 weeks). Based on pre-clinical data that the commonly prescribed medications metformin and atorvastatin have synergistic anti-breast cancer effects, this pre-surgical trial wil determine the effects of this combination on tumor tissue and blood collected from 40 women with newly diagnosed invasive breast cancer. The information learned from this preliminary study will be directly used to design and plan larger studies with this drug combination in patients with curable breast cancer.
Filed on November 05, 2014.
Tell us what you know about Kevin Kalinsky's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.